

BILL SUMMARY
1st Session of the 59th Legislature

Bill No.:	HB2107
Version:	CS
Request Number:	7479
Author:	Pae
Date:	3/8/2023
Impact:	Minimal increase in state appropriations.

Research Analysis

The committee substitute for HB 2107 establishes the Oklahoma Psilocybin Research Pilot Program. The measure allows a university or other institution of higher education located in Oklahoma, or a research facility that has entered into a memorandum of agreement with a university or institution of higher education located in Oklahoma, may conduct scientific research and pilot programs on psilocybin and psilocyn for the treatment of persons 18 years of age or older who experience any of the following medical conditions:

- Post-traumatic stress disorder
- Treatment-resistant/refractory depression
- Treatment-resistant/refractory anxiety
- Treatment-resistant/refractory obsessive-compulsive disorder
- Traumatic brain injury
- Early-stage dementia
- Palliative care
- End-of-life care
- Opioid use disorder
- Moderate to severe chronic pain

The measure requires researchers of psilocybin or psilocyn to register with OSBI and pay a \$140.00 annual registration fee, and outlines the information that must be submitted to the State Department of Health.

The measure limits universities to one memorandum of agreement with a research facility for the purposes of conducting scientific research, outlines the manner in which studies must be conducted, and provides legal protections for scientific researchers or physicians operating under a valid registration.

The measure also outlines that researching entities must submit a written report to the President Pro Tempore of the Oklahoma State Senate and the Speaker of the Oklahoma House of Representatives containing the results of the studies conducted and any recommendations for legislative or other actions not later than December 1, 2026.

Prepared By: Matthew Brenchley

Fiscal Analysis

In its current form, HB2107 allows, under certain conditions, universities, other higher education institutions, and research facilities to conduct scientific research and pilot programs on psilocybin and psilocyn for medical use. Officials with the Oklahoma State Department of

Health (OSDH) indicate that income generated from the fees outlined in this bill will be used to maintain a list of researchers, rendering the fiscal impact insignificant for OSDH. The Department of Agriculture, Food and Forestry (ODAFF) provided a similar statement, indicating that income generated will be consumed by administrative costs. Officials at ODAFF believe that as the measure only requires a registration fee for the initial registration, but also requires yearly updated registration, the fees in future years will not be sufficient to cover the associated administrative costs.

Prepared By: Zachary Penrod, House Fiscal Staff

Other Considerations

None.